Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Analysis of human papillomavirus E7 protein status in C-33A cervical cancer cells

  • 386 Accesses

  • 2 Citations

Abstract

High-risk human papillomaviruses (HPV) are the main etiologic factor for the development of cervical cancer. Infections by these viruses have been detected in virtually all cervical cancers. C-33A is one of the rare cervical cancer derived cell lines considered as HPV-negative. Employing monoclonal antibodies raised against a conformational epitope of the HPV-16 E7 oncoprotein, we present evidence suggesting that E7-positive cells can be sporadically and transiently detected in C-33A cell cultures. Immunoblotting with affinity-purified rabbit polyclonal anti-HPV 16 E7 antisera and q-RT-PCR analysis suggest that these cells do probably not express HPV-16 E7. Moreover, we show that the HPV E7 protein level differs considerably between individual cells in cultures of several established cervical cancer cell lines. Our data suggest that expression of the E7 protein is variable in established cervical cancer cell lines including C-33A cells.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    H. zur Hausen, Nat. Rev. Cancer 2, 342–350 (2002)

  2. 2.

    R.D. Burk, A. Harari, Z. Chen, Virology 445, 232–243 (2013)

  3. 3.

    R. Ghittoni, R. Accardi, U. Hasan, T. Gheit, B. Sylla, M. Tommasino, Virus Genes 40, 1–13 (2010)

  4. 4.

    M.E. McLaughlin-Drubin, K. Münger, Virology 384, 335–344 (2009)

  5. 5.

    D. Pim, L. Banks, APMIS 118, 471–493 (2010)

  6. 6.

    T. Crook, J.P. Morgenstern, L. Crawford, L. Banks, EMBO J. 8, 513–519 (1989)

  7. 7.

    D.E. Wazer, X.L. Liu, Q. Chu, Q. Gao, V. Band, Proc. Natl. Acad. Sci. USA 92, 3687–3691 (1995)

  8. 8.

    R.R. Riley, S. Duensing, T. Brake, K. Münger, P.F. Lambert, J.M. Arbeit, Cancer Res. 63, 4862–4871 (2003)

  9. 9.

    J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J. Snijders, J. Peto, C.J. Meijer, N. Muñoz, J. Pathol. 189, 12–19 (1999)

  10. 10.

    N. Muñoz, F.X. Bosch, S. de Sanjosé, R. Herrero, X. Castellsagué, K.V. Shah, P.J.F. Snijders, C.J.L.M. Meijer, N. Engl, J. Med. 348, 518–527 (2003)

  11. 11.

    G. Clifford, S. Franceschi, M. Diaz, N. Munoz, L.L. Villa, Vaccine 24(Suppl 3), S3/26-34 (2006)

  12. 12.

    J. Doorbar, W. Quint, L. Banks, I.G. Bravo, M. Stoler, T.R. Broker, M.A. Stanley, Vaccine 30(Suppl 5), F55–F70 (2012)

  13. 13.

    J.M. Walboomers, C.J. Meijer, J. Pathol. 181, 253–254 (1997)

  14. 14.

    N. Auersperg, J. Natl Cancer Inst. 32, 135–163 (1964)

  15. 15.

    C. Yee, I. Krishnan-Hewlett, C.C. Baker, R. Schlegel, P.M. Howley, Am. J. Pathol. 119, 361–366 (1985)

  16. 16.

    M. Scheffner, K. Munger, J.C. Byrne, P.M. Howley, Proc. Natl. Acad. Sci. USA 88, 5523–5527 (1991)

  17. 17.

    K. Dreier, R. Scheiden, B. Lener, D. Ehehalt, H. Pircher, E. Muller-Holzner, U. Rostek, A. Kaiser, M. Fiedler, S. Ressler, S. Lechner, A. Widschwendter, J. Even, C. Capesius, P. Jansen-Durr, W. Zwerschke, Virology 409, 54–68 (2011)

  18. 18.

    K. Seedorf, T. Oltersdorf, G. Krammer, W. Rowekamp, EMBO J. 6, 139–144 (1987)

  19. 19.

    D. Morandell, U. Rostek, V. Bouvard, B. Campo-Fernandez, M. Fiedler, P. Jansen-Durr, W. Zwerschke, Virology 379, 20–29 (2008)

  20. 20.

    P. Boukamp, R.T. Petrussevska, D. Breitkreutz, J. Hornung, A. Markham, N.E. Fusenig, J. Cell Biol. 106, 761–771 (1988)

  21. 21.

    D. Ehehalt, B. Lener, H. Pircher, K. Dreier, H. Pfister, A.M. Kaufmann, S. Frangini, S. Ressler, E. Muller-Holzner, M. Schmitt, D. Hofler, U. Rostek, A. Kaiser, A. Widschwendter, W. Zwerschke, P. Jansen-Durr, J. Clin. Microbiol. 50, 246–257 (2012)

  22. 22.

    M. Fiedler, B. Campo-Fernández, A. Laich, B. Moser, P. Stöckl, P. Jansen-Dürr, W. Zwerschke, J. Virol. Methods 134, 30–35 (2006)

  23. 23.

    M.C. Mitterberger, S. Lechner, M. Mattesich, A. Kaiser, D. Probst, N. Wenger, G. Pierer, W. Zwerschke, Stem Cell Res. 9, 35–48 (2012)

  24. 24.

    M.S. Barbosa, D.R. Lowy, J.T. Schiller, J. Virol. 63, 1404–1407 (1989)

  25. 25.

    X. Liu, A. Clements, K. Zhao, R. Marmorstein, J. Biol. Chem. 281, 578–586 (2006)

  26. 26.

    O. Ohlenschlager, T. Seiboth, H. Zengerling, L. Briese, A. Marchanka, R. Ramachandran, M. Baum, M. Korbas, W. Meyer-Klaucke, M. Durst, M. Gorlach, Oncogene 25, 5953–5959 (2006)

  27. 27.

    S. Ressler, R. Scheiden, K. Dreier, A. Laich, E. Muller-Holzner, H. Pircher, D. Morandell, I. Stein, H.P. Viertler, F.R. Santer, A. Widschwendter, J. Even, P. Jansen-Durr, C. Capesius, W. Zwerschke, Clin. Cancer Res. 13, 7067–7072 (2007)

  28. 28.

    F.R. Santer, B. Moser, G.A. Spoden, P. Jansen-Durr, W. Zwerschke, Carcinogenesis 28, 2511–2520 (2007)

  29. 29.

    C.C. Baker, W.C. Phelps, V. Lindgren, M.J. Braun, M.A. Gonda, P.M. Howley, J. Virol. 61, 962–971 (1987)

  30. 30.

    H. Valdovinos-Torres, M. Orozco-Morales, A. Pedroza-Saavedra, L. Padilla-Noriega, F. Esquivel-Guadarrama, L. Gutierrez-Xicotencatl, Open Virol. J. 2, 15–23 (2008)

  31. 31.

    M.V. Jacobs, P.J. Snijders, A.J. van den Brule, T.J. Helmerhorst, C.J. Meijer, J.M. Walboomers, J. Clin. Microbiol. 35, 791–795 (1997)

  32. 32.

    M.H. Schiffman, H.M. Bauer, A.T. Lorincz, M.M. Manos, J.C. Byrne, A.G. Glass, D.M. Cadell, P.M. Howley, J. Clin. Microbiol. 29, 573–577 (1991)

  33. 33.

    B.J. Morris, Clin. Chem. Lab. Med. 43, 1171–1177 (2005)

  34. 34.

    Y. Xue, D. Lim, L. Zhi, P. He, J.P. Abastado, F. Thierry, Open Virol. J. 6, 163–172 (2012)

  35. 35.

    H. Johansson, D. Bzhalava, J. Ekström, E. Hultin, J. Dillner, O. Forslund, Virology 440, 1–7 (2013)

  36. 36.

    A. Pauck, B. Lener, M. Hoell, A. Kaiser, A.M. Kaufmann, W. Zwerschke, P. Jansen-Durr, J. Virol. 88, 5256–5262 (2014)

  37. 37.

    M. Fiedler, E. Müller-Holzner, H.P. Viertler, A. Widschwendter, A. Laich, G. Pfister, G.A. Spoden, P. Jansen-Dürr, W. Zwerschke, FASEB J 18, 1120–1122 (2004)

Download references

Acknowledgments

Work in WZs laboratory was supported by intramural funding from the University of Innsbruck. Work in PJDs laboratory was supported by the Austrian Science Funds.

Disclosure

PJD and WZ declare that they are listed as inventors on a patent application related to anti high-risk HPV E7 RabMAbs submitted by the Austrian Academy of Science (ÖAW) and AWS-Austria Wirtschaftsservice. The other authors declare no conflict of interest.

Author information

Correspondence to Werner Zwerschke.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kaiser, A., Jenewein, B., Pircher, H. et al. Analysis of human papillomavirus E7 protein status in C-33A cervical cancer cells. Virus Genes 50, 12–21 (2015). https://doi.org/10.1007/s11262-014-1129-x

Download citation

Keywords

  • Cervical cancer
  • HPV E7
  • CaSki
  • SiHa
  • C-33A
  • HeLa